全反式维甲酸在实体瘤中临床应用进展
Progress in the clinical application of all-trans-retinoic acid in solid tumors
阮聪 1钱佳佳 1杜琼 2翟青 2孙晓敏 3徐蕊1
作者信息
- 1. 复旦大学附属肿瘤医院闵行分院药剂科,上海 200240
- 2. 复旦大学附属肿瘤医院闵行分院药剂科,上海 200240;复旦大学附属肿瘤医院药剂科,上海 200032;复旦大学上海医学院肿瘤学系,上海 200032
- 3. 山东良福制药有限公司,山东济宁 272600
- 折叠
摘要
全反式维甲酸(all-trans-retinoic acid,ATRA)是治疗急性早幼粒细胞白血病(acute promyelocytic leukemia)的临床首选药物.然而近年来大量研究表明,ATRA可通过抑制肿瘤干细胞的免疫逃逸效应以及促进髓源性抑制细胞的分化等机制来维持人体正常免疫微环境,进而增强化疗、靶向和免疫治疗药物在实体瘤中的疗效.该文就ATRA在实体瘤中的临床研究进展作一综述,为其进一步临床应用提供参考.
Abstract
All-trans-retinoic acid(ATRA)is the clinical choice for the treatment of acute promyelocytic leukemia.However,in recent years,a large number of studies have shown that ATRA maintains the human normal immune microenvironment by inhibiting the immune escape effect of tumor stem cells and promoting the differentiation of myeloid-derived suppressor cells,and enhances the efficacy of chemotherapeutic drugs,targeted drugs and immunotherapy drugs in solid tumors.This paper reviewed the clinical trial progress of ATRA in solid tumors to provide a reference for its further clinical application.
关键词
全反式维甲酸/实体瘤/肿瘤干细胞/髓源性抑制细胞/免疫调节Key words
all-trans-retinoic acid/solid tumor/tumor stem cells/myeloid-derived suppressor cells/immunomodulation引用本文复制引用
基金项目
上海市闵行区卫生健康系统优秀青年药学人才计划(MWYJYX03)
上海市闵行区自然科学研究课题(2022MHZ040)
出版年
2024
NETL
NSTL
万方数据